CA2836946C - A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof - Google Patents

A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof Download PDF

Info

Publication number
CA2836946C
CA2836946C CA2836946A CA2836946A CA2836946C CA 2836946 C CA2836946 C CA 2836946C CA 2836946 A CA2836946 A CA 2836946A CA 2836946 A CA2836946 A CA 2836946A CA 2836946 C CA2836946 C CA 2836946C
Authority
CA
Canada
Prior art keywords
cyclosporine
crystalline form
eye
methods
csa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2836946A
Other languages
English (en)
French (fr)
Other versions
CA2836946A1 (en
Inventor
Kiomars Karami
Richard S. Graham
Anuradha V. Gore
Scott W. Smith
Ke Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2836946(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2836946A1 publication Critical patent/CA2836946A1/en
Application granted granted Critical
Publication of CA2836946C publication Critical patent/CA2836946C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2836946A 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof Active CA2836946C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27
US61/490,887 2011-05-27
PCT/US2012/039611 WO2012166610A1 (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Publications (2)

Publication Number Publication Date
CA2836946A1 CA2836946A1 (en) 2012-12-06
CA2836946C true CA2836946C (en) 2017-08-01

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836946A Active CA2836946C (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Country Status (19)

Country Link
US (4) US8772245B2 (https=)
EP (2) EP3521302A1 (https=)
JP (1) JP6163482B2 (https=)
KR (1) KR102079402B1 (https=)
CN (1) CN103649108B (https=)
AR (1) AR086586A1 (https=)
AU (4) AU2012262513B2 (https=)
BR (1) BR112013030554B1 (https=)
CA (1) CA2836946C (https=)
CL (1) CL2013003400A1 (https=)
IL (2) IL229475A0 (https=)
MX (1) MX362271B (https=)
MY (1) MY180581A (https=)
RU (1) RU2602062C2 (https=)
SG (1) SG10201607344UA (https=)
TW (1) TWI554522B (https=)
UA (1) UA113627C2 (https=)
WO (1) WO2012166610A1 (https=)
ZA (1) ZA201308665B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
ES2666191T3 (es) * 2011-11-15 2018-05-03 Allergan, Inc. Un proceso para la cristalización de la forma 2 de la ciclosporina A
RU2630970C2 (ru) * 2011-11-15 2017-09-15 Аллерган, Инк. Автоклавируемые взвеси циклоспорина а формы 2
RU2639393C2 (ru) * 2011-11-15 2017-12-21 Аллерган, Инк. Состав пролонгированного действия циклоспорина формы 2
JP2015519368A (ja) 2012-06-01 2015-07-09 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ類似体
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
MY196111A (en) 2014-07-18 2023-03-15 Allergan Inc Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
KR102287226B1 (ko) 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
WO2021224901A2 (en) * 2021-08-20 2021-11-11 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
EP4585605A1 (en) * 2022-10-20 2025-07-16 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
KR20250160895A (ko) 2023-03-20 2025-11-14 추가이 세이야쿠 가부시키가이샤 고리형 펩타이드의 공결정을 제조하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
CA2686234A1 (en) * 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
JP2011508776A (ja) * 2008-01-04 2011-03-17 アルコン ファーマシューティカルズ リミテッド 安定な水性シクロスポリン組成物

Also Published As

Publication number Publication date
CN103649108A (zh) 2014-03-19
UA113627C2 (xx) 2017-02-27
MY180581A (en) 2020-12-02
TWI554522B (zh) 2016-10-21
NZ719272A (en) 2017-10-27
EP3521302A1 (en) 2019-08-07
BR112013030554B1 (pt) 2020-12-15
MX2013013855A (es) 2014-02-17
EP2714720A1 (en) 2014-04-09
US20160083432A1 (en) 2016-03-24
IL290158A (en) 2022-03-01
JP6163482B2 (ja) 2017-07-12
SG10201607344UA (en) 2016-10-28
RU2602062C2 (ru) 2016-11-10
AU2012262513A1 (en) 2013-12-12
US8772245B2 (en) 2014-07-08
KR102079402B1 (ko) 2020-02-19
US9206228B2 (en) 2015-12-08
MX362271B (es) 2019-01-10
RU2013155033A (ru) 2015-07-20
US20140315827A1 (en) 2014-10-23
WO2012166610A1 (en) 2012-12-06
US20130023482A1 (en) 2013-01-24
ZA201308665B (en) 2014-07-30
AR086586A1 (es) 2014-01-08
AU2019204192A1 (en) 2019-07-04
BR112013030554A2 (pt) 2016-09-06
EP2714720B1 (en) 2018-12-26
US20210269484A1 (en) 2021-09-02
TW201311730A (zh) 2013-03-16
CA2836946A1 (en) 2012-12-06
AU2017265008A1 (en) 2017-12-07
AU2016203990A1 (en) 2016-06-30
NZ618213A (en) 2016-05-27
JP2014515372A (ja) 2014-06-30
AU2019204192B2 (en) 2021-02-04
AU2012262513B2 (en) 2016-03-17
CN103649108B (zh) 2017-03-29
KR20140047054A (ko) 2014-04-21
CL2013003400A1 (es) 2014-08-18
IL229475A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CA2836946C (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
US6254860B1 (en) Ocular treatment using cyclosporin-A derivatives
RU2639393C2 (ru) Состав пролонгированного действия циклоспорина формы 2
EP2779994B1 (en) Suspensions of cyclosporin a form 2
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
WO2006137426A1 (ja) 角結膜疾患の予防又は治療剤
NZ618213B2 (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
NZ719272B2 (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
HK1193117A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
HK1193117B (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
HK1202066B (en) Suspensions of cyclosporin a form 2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260126